FDA.reportPublic FDA data

Kisqali 200 MG (42) / Femara 2.5 MG (28) Daily Dose Carton

RxCUI
1923056
RxNorm name
Kisqali 200 MG (42) / Femara 2.5 MG (28) Daily Dose Carton
Display name
Kisqali 200 MG (42) / Femara 2.5 MG (28) Daily Dose Carton
Full name
Kisqali 200 MG (42) / Femara 2.5 MG (28) Daily Dose Carton
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:14

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
aa5e4446-19cd-4235-a382-5b48bf6c3b2f{28 (letrozole 2.5 MG Oral Tablet [Femara]) / 42 (ribociclib 200 MG Oral Tablet [Kisqali]) } Pack [Kisqali Femara Co-Pack 400] [BPCK] · Kisqali 400 MG - Femara 2.5 MG Daily Dose Carton [PSN] · Kisqali 200 MG (42) / Femara 2.5 MG (28) Daily Dose Carton [SY] · Kisqali 400 MG - Femara 2.5 MG Daily Dose Carton [SY]425These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI ® FEMARA ® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use Initial U.S. Approval: 201720250916